Even Though Lotus Health Group (SHSE:600186) Has Lost CN¥390m Market Cap in Last 7 Days, Shareholders Are Still up 137% Over 5 Years
Even Though Lotus Health Group (SHSE:600186) Has Lost CN¥390m Market Cap in Last 7 Days, Shareholders Are Still up 137% Over 5 Years
Lotus Health Group Company (SHSE:600186) shareholders might be concerned after seeing the share price drop 24% in the last quarter. But that doesn't change the fact that shareholders have received really good returns over the last five years. We think most investors would be happy with the 137% return, over that period. To some, the recent pullback wouldn't be surprising after such a fast rise. Of course, that doesn't necessarily mean it's cheap now.
在過去的一個季度,蓮花醫療集團公司(SHSE:600186)的股價下跌了24%,股東們可能會感到擔憂。 但這並不改變股東們在過去五年中獲得了非常好的回報的事實。我們認爲大多數投資者對這段時間的137%回報會感到滿意。對某些人來說,在快速上漲後出現回調並不奇怪。當然,這並不一定意味着現在便宜。
While this past week has detracted from the company's five-year return, let's look at the recent trends of the underlying business and see if the gains have been in alignment.
雖然過去的一週削弱了公司的五年回報,但讓我們看看業務的最近趨勢,並查看收益是否已對齊。
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
雖然一些人仍然相信有效市場假說,但已經證明市場是過度反應的動態系統,投資者並不總是理性的。一個不完美但簡單的方法來考慮公司市場看法的變化是比較每股收益(EPS)的變化和股價的波動。
During the last half decade, Lotus Health Group became profitable. Sometimes, the start of profitability is a major inflection point that can signal fast earnings growth to come, which in turn justifies very strong share price gains. Given that the company made a profit three years ago, but not five years ago, it is worth looking at the share price returns over the last three years, too. In fact, the Lotus Health Group stock price is 6.7% lower in the last three years. Meanwhile, EPS is up 22% per year. It would appear there's a real mismatch between the increasing EPS and the share price, which has declined -2.3% a year for three years.
在過去的半個十年裏,蓮花醫療集團盈利了。有時,盈利的開始是一個重要的轉折點,可以預示未來快速盈利增長,從而證明股價將大幅上漲。鑑於該公司三年前開始盈利,但五年前並沒有盈利,因此有必要查看過去三年的股價回報情況。事實上,蓮花醫療集團的股價在過去三年中下跌了6.7%。與此同時,每股收益每年增長22%。看起來逐漸增長的每股收益和股價之間存在實質性的不匹配,股價在過去三年每年下跌2.3%。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
該公司的每股收益(隨時間的推移)如下圖所示(單擊可查看確切數字)。
Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.
在購買或出售股票之前,我們始終建議對歷史增長趨勢進行仔細研究,可以在這裏找到相關信息。
A Different Perspective
不同的觀點
While it's never nice to take a loss, Lotus Health Group shareholders can take comfort that their trailing twelve month loss of 9.5% wasn't as bad as the market loss of around 17%. Of course, the long term returns are far more important and the good news is that over five years, the stock has returned 19% for each year. It could be that the business is just facing some short term problems, but shareholders should keep a close eye on the fundamentals. Before deciding if you like the current share price, check how Lotus Health Group scores on these 3 valuation metrics.
雖然承受虧損從來不是件好事,但蓮花保健集團的股東們可以安慰自己,最近十二個月的虧損爲9.5%,比市場虧損的大約17%要好一些。當然,長期回報更爲重要,令人振奮的消息是,這隻股票在過去五年中平均每年回報19%。可能是業務只是遇到了一些短期問題,但股東們應該密切關注基本面。在決定是否喜歡目前的股價之前,先檢查蓮花保健集團在這3個估值指標上的表現。
We will like Lotus Health Group better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying.
如果我們看到有一些內部人大量買進蓮花健康集團的話,我們會更喜歡它。在等待期間,查看這個免費的被低估的股票(主要是小市值股票)的列表,其中有相當多的內部人購買。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。